Advertisement




Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

Advertisement

Advertisement



Advertisement